Study Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
PCAR-019 (anti-CD19 CAR-T cells)BIOLOGICAL
No description available.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Suzhou | Jiangsu | China |